Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac. [electronic resource]
Producer: 20020924Description: 436-46 p. digitalISSN:- 0315-162X
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Arthritis, Rheumatoid -- drug therapy
- Cyclooxygenase 2
- Cyclooxygenase 2 Inhibitors
- Cyclooxygenase Inhibitors -- administration & dosage
- Diclofenac -- administration & dosage
- Double-Blind Method
- Female
- Humans
- Isoenzymes -- antagonists & inhibitors
- Liver Function Tests
- Male
- Meloxicam
- Membrane Proteins
- Middle Aged
- Placebos
- Prostaglandin-Endoperoxide Synthases
- Thiazines -- administration & dosage
- Thiazoles -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.